In Situ Exosomal MicroRNA Determination by Target-Triggered SERS and Fe3O4@TiO2-Based Exosome Accumulation
Autor: | Shuqin Jiang, Zhiwei Sun, Qing Li, Rui Xiao, Chongwen Wang, Yuanfeng Pang |
---|---|
Rok vydání: | 2021 |
Předmět: |
Fluid Flow and Transfer Processes
In situ Chemistry Process Chemistry and Technology 010401 analytical chemistry Bioengineering 02 engineering and technology 021001 nanoscience & nanotechnology 01 natural sciences Exosome Microvesicles 0104 chemical sciences Reverse transcription polymerase chain reaction Biochemistry microRNA RNA extraction Locked nucleic acid Liquid biopsy 0210 nano-technology Instrumentation |
Zdroj: | ACS Sensors. 6:852-862 |
ISSN: | 2379-3694 |
DOI: | 10.1021/acssensors.0c01900 |
Popis: | Exosomal microRNAs (miRNAs) have been proved to be important biomarkers for the early diagnosis of cancers. However, the accurate quantification of exosomal miRNAs is hampered either by laborious exosome isolation and lysis or by RNA extraction and the amplification process. Here, we reported an in situ platform for direct exosomal miRNAs from serum samples. First, locked nucleic acid (LNA)-modified Au@DTNB (DTNB is the Raman reporter molecule 5,5'-dithiobis-(2-nitrobenzoic acid)) was synthesized as surface-enhanced Raman scattering (SERS) tags to enter into exosomes and assemble with target miRNAs to induce hot-spot SERS signals. Second, Fe3O4@TiO2 nanoparticles were added to enrich the exosomes through affinity interaction of the TiO2 shell for further SERS detection. Based on the platform, target miRNAs can be directly qualified in situ with a detection limit of 0.21 fM, which is better or comparable with quantitative reverse transcription polymerase chain reaction (qRT-PCR) and other in situ methods reported before. Moreover, neither capture antibody nor ultracentrifugation pretreatment was needed in the whole detection procedure. Using exosomal miRNA-10b as a proof of concept, pancreatic ductal adenocarcinoma (PDAC) patients can be recognized from normal controls (NCs) with an accuracy of 99.6%. The simple and sensitive in situ exosomal miRNA detection assay can be seen as a noninvasive liquid biopsy assay for clinical cancer diagnostic adaption. |
Databáze: | OpenAIRE |
Externí odkaz: |